ArticleScientific reports2025

A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer.

Shuailei Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.